Ascelia Pharma AB

Ascelia Pharma AB Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 “We are very pleased with the outcome of our meeting with the FDA and look forward to advancing the NDA submission for Orviglance in order to submit in the middle of the year, as planned. This meeting with the FDA is another significant step forward in bringing Orviglance to market,” said Magnus Corfitzen, CEO of Ascelia Pharma AB. #AsceliaPharma #update #NDA

Did you miss when Magnus Corfitzen, CEO at Ascelia Pharma AB presented at Carnegie Investment Bank Healthcare day yesterday? Now you can watch the video and hear more about our latest updates and outlook. #AsceliaPharma #oncology #MRI #Unmetneed

Join us on Wednesday, March 26th at 14:05 for an insightful presentation by our CEO, Magnus Corfitzen, at the upcoming investor seminar hosted by Økonomisk Ugebrev A/S. This will be an opportunity to discover the latest developments and future plans of Ascelia Pharma AB. To register: 👇

Today is World Kidney Day Thank you World Kidney Day for raising awareness about the importance of recognizing risk factors and ensuring timely testing to enhance early detection and intervention. This year's theme, "Are Your Kidneys OK? Detect early, protect kidney health," underscores the critical need for proactive measures to safeguard kidney health. Let's continue to support and promote initiatives that advance kidney health for everyone. #WorldKidneyDay #KidneyHealth #EarlyDetection #HealthAwareness

Join Julie Waras Brogren, Deputy CEO and Jennie Wilborgsson, VP Clinical Development at Ascelia Pharma AB at the Nexus Conference in Basel on March 13-14, 2025, and be part of the conversation driving the future of biopharma! 🌟 Julie Waras Brogren will share insights on "Optimizing Supply Chain Strategies for Product Launches" and join a dynamic panel discussion on "Partnerships in Supply Procurement: Driving Innovation and Collaboration." 🌟 Jennie Wilborgsson will delve into "Evaluating the Right Outsourcing Approach from a Biotech Perspective." For more information on the conference: https://lnkd.in/dbxy9NKX #BioPharma #SupplyChain #ClinicalTrials #Innovation #Collaboration #Networking

Magnus Corfitzen, CEO at Ascelia Pharma AB will present at Carnegie Investment Bank Healthcare day in Stockholm on March 13, 2025 at 10:50 📆 . Don't miss this opportunity to hear about our latest advancements and how we are addressing unmet medical needs. The presentation will be available on our website: www.ascelia.com #update #AsceliaPharma #Unmetneed

March is #NationalKidneyMonth! 🩺 Let's raise awareness about kidney disease! This year, the focus is on taking charge of our health. Chronic kidney disease (CKD) affects 10% of the global population and can lead to serious complications. By adopting a healthy lifestyle, we can better manage and prevent CKD. To read more on how to manage CKD: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Ascelia Pharma AB works to improve the life of people living with rare cancer conditions and kidney disease. #KidneyHealth #NationalKidneyMonth #HealthyLiving #NIDDK

Today is #Rare Disease Day We thank Rare Disease Day and the National Organization for Rare Disorders for advocating equal opportunities for people with rare diseases. At Ascelia Pharma AB, we strive to improve the lives of people with rare cancer conditions by providing fair and equal access to diagnosis and care. #Showyourstripes #RareDiseaseDay #LightupForRare

Did you miss today's presentation of full-year and Q4 report with Julie Waras Brogren, Deputy CEO of Ascelia Pharma AB? Take a few minutes to tune in and catch up on the updates using the link below! You can also read the entire press release and the report on our website: www.ascelia.com #asceliapharma #unmetneed #oncology

Today Ascelia Pharma AB released it's Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study “In 2024, we have met several major milestones with the successful results from our Orviglance pivotal Phase 3 study, SPARKLE. The positive headline results and subsequent Full Study Report mark the completion of clinical development for Orviglance. The results showed that Orviglance significantly improved visualization of focal liver lesions, successfully meeting the primary endpoint with statistical significance for all three readers (<0.001). The results of the secondary endpoint analysis further reinforce the successful study outcomes and support the NDA process and potential clinical value of Orviglance. It’s encouraging to see how the medical community has welcomed Orviglance with the acceptance of SPARKLE Phase 3 data for presentation in four oral presentations and three abstracts at key scientific conferences thus far. We are in a strong position to deliver on our key priorities ahead; to submit the New Drug Application (NDA) for Orviglance to the US Food and Drug Administration (FDA) expected mid-2025 and to continue advancing the dialogue with potential partners to commercialize Orviglance and make it available to patients in need of a high-quality liver imaging option without gadolinium related safety risks. With the fully subscribed SEK 105 million Rights Issue financing in Q3 2024, our cash runway extends until late 2025; well beyond the NDA submission for Orviglance. Our runway can be significantly extended with financing from warrants and partnering.”, said Magnus Corfitzen, CEO at Ascelia Pharma AB Pharma. #fullyearreport2024 #orphanonconlogy #MRI